VEGF inhibitors for anti-angiogenic therapy
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Video |
| Language: | English |
| Published: |
London :
Henry Stewart Talks,
2007.
|
| Series: | Henry Stewart talks. Biomedical & life sciences collection. Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease.
|
| Subjects: | |
| Online Access: | https://hstalks.com/bs/912/ Series |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Add Tag MARC
| LEADER | 00000ngm a2200000 a 4500 | ||
|---|---|---|---|
| 001 | HST1268_1_2 | ||
| 003 | UkLoHST | ||
| 006 | m c | ||
| 007 | cr|cna|||a|||| | ||
| 007 | vz|czazum | ||
| 008 | 080121s2007 enk|||||||||||s|||v|eng d | ||
| 028 | 5 | 0 | |a 1268 |b Henry Stewart Talks |
| 035 | |a (UkLoHST)912 | ||
| 035 | |a (UkLU-K)AC000391090 | ||
| 040 | |a UkLU-K |b eng |c UkLU-K | ||
| 100 | 1 | |a Alitalo, Kari. |4 spk |9 110696 | |
| 245 | 1 | 0 | |a VEGF inhibitors for anti-angiogenic therapy |h [electronic resource] / |c Kari Alitalo. |
| 260 | |a London : |b Henry Stewart Talks, |c 2007. | ||
| 300 | |a 1 online resource (1 streaming video file (71 min.) : |b color, sound). | ||
| 490 | 1 | |a Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease, |x 2056-452X | |
| 500 | |a Animated audio-visual presentation with synchronized narration. | ||
| 500 | |a Title from title frames. | ||
| 505 | 0 | |a Contents: Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist monoclonal antibodies -- Functional properties of antagonist antibodies to VEGFR-3 -- In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis -- Inhibition of pathological vessel growth in the cornea -- Anti-angiogenic effect of antibodies to VEGFR-3 in tumors -- Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 -- Role of VEGFR-3 in normal and pathological immune response. | |
| 506 | |a Access restricted to subscribers. | ||
| 538 | |a Mode of access: World Wide Web. | ||
| 650 | 0 | |a Monoclonal antibodies. |9 110697 | |
| 650 | 0 | |a Vascular endothelial growth factors |x Antagonists. |9 110698 | |
| 650 | 2 | |a Angiogenesis Inducing Agents. |9 110699 | |
| 650 | 2 | |a Neovascularization, Physiologic. |9 110700 | |
| 650 | 2 | |a Receptors, Vascular Endothelial Growth Factor. |9 110701 | |
| 650 | 2 | |a Signal Transduction. |9 110702 | |
| 650 | 2 | |a Vascular Endothelial Growth Factor Receptor-3 |x antagonists & inhibitors. |9 110703 | |
| 650 | 2 | |a Vascular Endothelial Growth Factor Receptor-3 |x metabolism. |9 110704 | |
| 650 | 2 | |a Vascular Endothelial Growth Factor Receptor-3. |9 110705 | |
| 830 | 0 | |a Henry Stewart talks. |p Biomedical & life sciences collection. |p Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease. |9 110706 | |
| 856 | 4 | 0 | |u https://hstalks.com/bs/912/ |
| 856 | 4 | 2 | |u https://hstalks.com/bs/p/38/ |3 Series |
| 999 | |c 215964 |d 215963 | ||
VEGF inhibitors for anti-angiogenic therapy